10X Genomics Inc
TXG12.005USD
+0.085+0.71%
Market hours （ET）Quotes delayed by 15 min
1.48BMarket Cap
LossP/E TTM
More Details of 10X Genomics Inc Company
10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others.
Company Info
Ticker SymbolTXG
Company name10X Genomics Inc
IPO dateSep 12, 2019
Founded at2012
CEOMr. Serge Wilson Saxonov, Ph.D.
Number of employees1306
Security typeOrdinary Share
Fiscal year-endSep 12
Address6230 Stoneridge Mall Road
CityPLEASANTON
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code94588
Phone19254017300
Websitehttps://www.10xgenomics.com/
Ticker SymbolTXG
IPO dateSep 12, 2019
Founded at2012
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Serge Wilson Saxonov, Ph.D.
Mr. Serge Wilson Saxonov, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
1.07M
-0.09%
Dr. John R. Stuelpnagel
Dr. John R. Stuelpnagel
Independent Chairman of the Board
Independent Chairman of the Board
369.61K
+4.34%
Whitaker (Eric S)
Whitaker (Eric S)
Chief Legal Officer
Chief Legal Officer
202.20K
+29.09%
Mr. Sridhar (Sri) Kosaraju
Mr. Sridhar (Sri) Kosaraju
Independent Director
Independent Director
59.45K
+34.83%
Dr. Benjamin J. Hindson, Ph.D.
Dr. Benjamin J. Hindson, Ph.D.
President, Co-Founder, Chief Scientific Officer, Director
President, Co-Founder, Chief Scientific Officer, Director
52.17K
-12.55%
Ms. Kimberly J. (Kim) Popovits
Ms. Kimberly J. (Kim) Popovits
Independent Director
Independent Director
28.62K
+115.82%
Dr. Shehnaaz Suliman, M.D.
Dr. Shehnaaz Suliman, M.D.
Independent Director
Independent Director
28.62K
+115.82%
Mr. Adam S. Taich
Mr. Adam S. Taich
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Alan V. Mateo
Mr. Alan V. Mateo
Independent Director
Independent Director
--
--
Dr. Sarah A. Teichmann
Dr. Sarah A. Teichmann
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Serge Wilson Saxonov, Ph.D.
Mr. Serge Wilson Saxonov, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
1.07M
-0.09%
Dr. John R. Stuelpnagel
Dr. John R. Stuelpnagel
Independent Chairman of the Board
Independent Chairman of the Board
369.61K
+4.34%
Whitaker (Eric S)
Whitaker (Eric S)
Chief Legal Officer
Chief Legal Officer
202.20K
+29.09%
Mr. Sridhar (Sri) Kosaraju
Mr. Sridhar (Sri) Kosaraju
Independent Director
Independent Director
59.45K
+34.83%
Dr. Benjamin J. Hindson, Ph.D.
Dr. Benjamin J. Hindson, Ph.D.
President, Co-Founder, Chief Scientific Officer, Director
President, Co-Founder, Chief Scientific Officer, Director
52.17K
-12.55%
Ms. Kimberly J. (Kim) Popovits
Ms. Kimberly J. (Kim) Popovits
Independent Director
Independent Director
28.62K
+115.82%
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Consumables
115.36M
74.48%
Products and services revenue
17.06M
11.01%
Instruments
14.81M
9.57%
Services
7.65M
4.94%
By RegionUSD
Name
Revenue
Proportion
United States
86.82M
56.05%
Europe, the Middle East and Africa
31.89M
20.59%
China
16.88M
10.90%
Asia Pacific
15.54M
10.03%
Americas
3.75M
2.42%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Consumables
115.36M
74.48%
Products and services revenue
17.06M
11.01%
Instruments
14.81M
9.57%
Services
7.65M
4.94%
Shareholding Stats
Updated: Fri, May 23
Updated: Fri, May 23
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
ARK Investment Management LLC
11.56%
The Vanguard Group, Inc.
9.99%
Fidelity Management & Research Company LLC
7.72%
Millennium Management LLC
4.98%
BlackRock Institutional Trust Company, N.A.
4.87%
Other
60.88%
Shareholders
Shareholders
Proportion
ARK Investment Management LLC
11.56%
The Vanguard Group, Inc.
9.99%
Fidelity Management & Research Company LLC
7.72%
Millennium Management LLC
4.98%
BlackRock Institutional Trust Company, N.A.
4.87%
Other
60.88%
Shareholder Types
Shareholders
Proportion
Investment Advisor
45.04%
Investment Advisor/Hedge Fund
22.18%
Hedge Fund
19.03%
Bank and Trust
5.32%
Research Firm
5.16%
Venture Capital
3.69%
Individual Investor
1.92%
Pension Fund
0.68%
Family Office
0.30%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
656
115.46M
103.93%
-12.51M
2025Q1
687
115.67M
104.27%
-8.84M
2024Q4
689
107.08M
98.92%
-12.41M
2024Q3
682
106.90M
100.39%
-9.08M
2024Q2
691
105.36M
99.70%
-5.09M
2024Q1
762
106.36M
101.17%
-3.12M
2023Q4
817
100.80M
96.01%
-9.73M
2023Q3
835
96.86M
93.80%
-12.55M
2023Q2
857
94.98M
96.77%
-15.37M
2023Q1
864
95.62M
97.55%
-9.91M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
ARK Investment Management LLC
12.85M
11.56%
+901.66K
+7.55%
Mar 31, 2025
The Vanguard Group, Inc.
11.09M
9.99%
+184.54K
+1.69%
Mar 31, 2025
Fidelity Management & Research Company LLC
8.58M
7.72%
-2.75M
-24.30%
Mar 31, 2025
Millennium Management LLC
5.53M
4.98%
+156.13K
+2.90%
Apr 01, 2025
BlackRock Institutional Trust Company, N.A.
5.41M
4.87%
-108.37K
-1.96%
Mar 31, 2025
Sumitomo Mitsui Trust Bank, Limited
5.36M
4.83%
+5.36M
--
Mar 31, 2025
UBS Asset Management (Switzerland)
4.10M
3.69%
+2.13M
+108.14%
Mar 31, 2025
Two Sigma Investments, LP
3.17M
2.85%
+614.32K
+24.04%
Mar 31, 2025
UBS Asset Management (Americas) LLC
2.90M
2.61%
+2.85M
+4.95K%
Mar 31, 2025
BofA Global Research (US)
2.56M
2.3%
+2.03M
+386.97%
Mar 31, 2025
View more
Related ETFs
Updated: Sun, Jul 6
Updated: Sun, Jul 6
Name
Proportion
ARK Genomic Revolution ETF
3.47%
ARK Innovation ETF
1.55%
WisdomTree BioRevolution Fund
1.48%
Global X Genomics & Biotechnology ETF
1.35%
Invesco NASDAQ Future Gen 200 ETF
0.54%
First Trust Nasdaq Lux Digi Health Solutions ETF
0.36%
ProShares Ultra Nasdaq Biotechnology
0.15%
Invesco Nasdaq Biotechnology ETF
0.11%
iShares Biotechnology ETF
0.1%
Goldman Sachs Innovate Equity ETF
0.08%
View more
ARK Genomic Revolution ETF
Proportion3.47%
ARK Innovation ETF
Proportion1.55%
WisdomTree BioRevolution Fund
Proportion1.48%
Global X Genomics & Biotechnology ETF
Proportion1.35%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.54%
First Trust Nasdaq Lux Digi Health Solutions ETF
Proportion0.36%
ProShares Ultra Nasdaq Biotechnology
Proportion0.15%
Invesco Nasdaq Biotechnology ETF
Proportion0.11%
iShares Biotechnology ETF
Proportion0.1%
Goldman Sachs Innovate Equity ETF
Proportion0.08%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
